Prostate cancer is one of the most common cancers in men.
In case of metastatic disease, bone manifestation is presented in 85-90% of the patients. The new targeted treatments are the denosumab RANK-ligand monoclonal antibody and Ra-223-chloride radioisotope therapy. This paper summarizes the treatment possibilities of bone metastasis and presents the results of phase III trials of denosumab and Ra-223-chloride. The upcoming change in financial support underlines the actuality of this paper.
Written by:
Géczi L, Sinkovics I. Are you the author?
Kemoterápia C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary; Nukleáris Medicina Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
Reference: Magy Onkol. 2014 Sep 26;58(3):199-203.
PubMed Abstract
PMID: 25260084
Article in Hungarian.